Table 5.

Study Outcomes Stratified by Race

Endpoints	AA (n = 89)	White (n = 107)	P-value (2-sided)
% Enrollment in Therapeutic Trials	4.5%	11.2%	0.087
Baseline Surveya
Likelihood to Enroll Scoreb	3.2 ± 1.1	3.5 ± 1.2	0.173
% Responded “Extremely likely to enroll”	12%	23%	0.050*
Trust in Doctorsc	77.1 ± 26.9	85.4 ± 20.7	0.019*
Altruismc	75.6 ± 28.0	76.0 ± 25.3	0.907
Personal Benefitsc	84.1 ± 19.9	81.6 ± 20.1	0.374
Negative Aspectsc	69.7 ± 25.5	55.1 ± 26.8	< 0.001**
Inconveniencec	45.4 ± 31.9	36.3 ± 28.2	0.035*
Follow-Up Surveya
Likelihood to Enroll Scoreb	3.1 ± 1.3	3.2 ± 1.4	0.636
% Responded “Extremely likely to enroll”	15%	22%	0.194
Trust in Doctorsc	77.0 ± 27.5	85.3 ± 22.7	0.025*
Altruismc	72.9 ± 28.2	69.1 ± 30.5	0.372
Personal Benefitsc	80.5 ± 20.7	79.5 ± 21.2	0.740
Negative Aspectsc	71.8 ± 23.9	58.4 ± 24.1	<0.001**
Inconveniencec	45.7 ± 29.9	39.2 ± 27.5	0.119

^aMean ± standard deviation

^bValues scored on (1–5) scale

^cSubscales were standardized into scores of 0–100

^*P-value ≤ 0.05;

^**P-value ≤ 0.01